Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
PLoS One
    January 2024
  1. JIWA NA, Ketang'enyi E, Nganyanyuka K, Mbwanji R, et al
    Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania.
    PLoS One. 2024;19:e0292424.
    >> Share

  2. PEREZ-MARTINEZ L, Romero L, Verdugo-Sivianes EM, Munoz-Galvan S, et al
    Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.
    PLoS One. 2024;19:e0286201.
    >> Share

  3. SHIDA H, Komamine M, Kajiyama K, Waki T, et al
    Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan.
    PLoS One. 2024;19:e0297679.
    >> Share

  4. FAYA CASTILLO JE, Zapata Dongo RJ, Wong Chero PA, Infante Varillas SF, et al
    Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
    PLoS One. 2024;19:e0295966.
    >> Share

  5. WU L, Wang Q, Gao QC, Shi GX, et al
    Potential mechanisms and drug prediction of Rheumatoid Arthritis and primary Sjogren's Syndrome: A public databases-based study.
    PLoS One. 2024;19:e0298447.
    >> Share

  6. RUNGMAITREE S, Werarak P, Pumpradit W, Phongsamart W, et al
    A pilot program of HIV pre-exposure prophylaxis in Thai youth.
    PLoS One. 2024;19:e0298914.
    >> Share

  7. KAMAU SG, Akatusasira R, Namatovu A, Kibet E, et al
    The level of antiretroviral therapy (ART) adherence among orphan children and adolescents living with HIV/AIDS: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0295227.
    >> Share

  8. MINJA M, Mbilinyi T, Mkinga B, Philipo EG, et al
    Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction of integrase inhibitors antiretroviral based regimens among People Living with HIV in Tanzania.
    PLoS One. 2024;19:e0294940.
    >> Share

  9. SHAMU T, Egger M, Mudzviti T, Chimbetete C, et al
    Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    PLoS One. 2024;19:e0293162.
    >> Share

  10. SACKEYA E, Beru MM, Angmortey RN, Opoku DA, et al
    Survival trends among people living with human immunodeficiency virus on antiretroviral treatment in two rural districts in Ghana.
    PLoS One. 2024;19:e0290810.
    >> Share

    January 2023
  11. FROLA CE, Aristegui I, Figueroa MI, Radusky PD, et al
    Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
    PLoS One. 2023;18:e0279996.
    >> Share


  12. Correction: Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PLoS One. 2023;18:e0281190.
    >> Share

  13. CHI BH, Sebikari D, Brummel SS, DeMarrais P, et al
    Progesterone and prolactin levels in pregnant women living with HIV who delivered preterm and low birthweight infants: A nested case-control study.
    PLoS One. 2023;18:e0280730.
    >> Share

  14. BYONANEBYE DM, Polizzotto MN, Parkes-Ratanshi R, Musaazi J, et al
    Prevalence and incidence of hypertension in a heavily treatment-experienced cohort of people living with HIV in Uganda.
    PLoS One. 2023;18:e0282001.
    >> Share

  15. BEAUCHAMP G, Hosek S, Donnell DJ, Chan KCG, et al
    Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
    PLoS One. 2023;18:e0281728.
    >> Share

  16. HERON JE, McManus H, Vickers T, Ryan K, et al
    Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
    PLoS One. 2023;18:e0280339.
    >> Share

  17. MENGISTU ST, Ghebremeskel GG, Achila OO, Abrehe MB, et al
    Prevalence and factors associated with pediatric HIV therapy failure in a tertiary hospital in Asmara, Eritrea: A 15-year retrospective cohort study.
    PLoS One. 2023;18:e0282642.
    >> Share

  18. PERETTI M, Rebaudet S, Chiche L, Pegliasco H, et al
    Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study.
    PLoS One. 2023;18:e0283165.
    >> Share

  19. ADEYEMI OA, Nowak RG, Marzinke M, Morgan D, et al
    Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria.
    PLoS One. 2023;18:e0282999.
    >> Share

  20. BAASSI M, Moussaoui M, Soufi H, Rajkhowa S, et al
    Towards designing of a potential new HIV-1 protease inhibitor using QSAR study in combination with Molecular docking and Molecular dynamics simulations.
    PLoS One. 2023;18:e0284539.
    >> Share

  21. WECHE M, DeSantis AJ, McGee MY, Enten GA, et al
    Effects of chemokine (C-C motif) receptor 2 and 3 antagonists in rat models of hemorrhagic shock.
    PLoS One. 2023;18:e0284472.
    >> Share

  22. NIU D, Tang H, Chen F, Zhao D, et al
    Treatment failure and associated factors among people living with HIV on highly active antiretroviral therapy in mainland China: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0284405.
    >> Share

  23. VAN DEN HOF M, Smit C, Rossum AMCV, Fraaij PLA, et al
    Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands.
    PLoS One. 2023;18:e0284395.
    >> Share

  24. VOLKOW P, Chavez Galan L, Ramon-Luing L, Cruz-Velazquez J, et al
    Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial.
    PLoS One. 2023;18:e0280209.
    >> Share

  25. ZENIN V, Tsedilin A, Yurkova M, Siniavin A, et al
    Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities.
    PLoS One. 2023;18:e0286752.
    >> Share

  26. SMITH C, Fought AJ, Sung JF, McKinney JR, et al
    Congenital malformations and preeclampsia associated with integrase inhibitor use in pregnancy: A single-center analysis.
    PLoS One. 2023;18:e0276473.
    >> Share

  27. ROSEN EP, White N, Gilliland WM Jr, Gerona RR, et al
    Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305.
    PLoS One. 2023;18:e0287449.
    >> Share

  28. PENNER J, Ombajo LA, Otieno D, Nkuranga J, et al
    High rates of kidney impairment among older people (>/= 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya.
    PLoS One. 2023;18:e0285787.
    >> Share

  29. SAHAY S, Bangar S, Chandhiok N
    Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men (MSM) and transgender women (TGW) in India: Study protocol.
    PLoS One. 2023;18:e0287454.
    >> Share

  30. PINKOH R, Rodsiri R, Wainipitapong S
    Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com(R), Lexicomp(R), and Epocrates(R).
    PLoS One. 2023;18:e0287575.
    >> Share

  31. NATUKUNDA E, Szubert A, Otike C, Namyalo I, et al
    Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.
    PLoS One. 2023;18:e0288877.
    >> Share

  32. TUKEI VJ, Herrera N, Masitha M, Masenyetse L, et al
    Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
    PLoS One. 2023;18:e0288619.
    >> Share

  33. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    >> Share

  34. SQUILLACE N, Ricci E, Maggi P, Taramasso L, et al
    Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
    PLoS One. 2023;18:e0289132.
    >> Share

  35. SHOAIB TH, Ibraheem W, Abdelrahman M, Osman W, et al
    Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
    PLoS One. 2023;18:e0289887.
    >> Share

  36. MBEBI ENONE PJ, Penda CI, Ngondi G, Fokam J, et al
    High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon.
    PLoS One. 2023;18:e0289426.
    >> Share

  37. KIM J, Newcomb CW, Carbonari DM, Torgersen J, et al
    Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016.
    PLoS One. 2023;18:e0290889.
    >> Share

  38. MENDOZA I, Lazaro A, Espinosa A, Sanchez L, et al
    Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
    PLoS One. 2023;18:e0291480.
    >> Share

  39. SOUZA KM, Carrasco G, Rojas-Cortes R, Michel Barbosa M, et al
    Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.
    PLoS One. 2023;18:e0284006.
    >> Share

  40. MOUSAVI MOVAHED SM, Akhavizadegan H, Dolatkhani F, Akbarpour S, et al
    Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study.
    PLoS One. 2023;18:e0292746.
    >> Share

  41. LEUNG V, Gill S, Llanes A, Khawaja A, et al
    A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    PLoS One. 2023;18:e0293302.
    >> Share

  42. AKISO M, Ameka M, Naidoo K, Langat R, et al
    Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy.
    PLoS One. 2023;18:e0286436.
    >> Share

  43. NIGHTINGALE S, Ssemmanda S, Tucker LM, Eastman RW, et al
    Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome.
    PLoS One. 2023;18:e0288055.
    >> Share

  44. BLAYLOCK JM, Ewers EC, Bianchi EJ, King DB, et al
    Risk of sexually transmitted infections among U.S. military service members in the setting of HIV pre-exposure prophylaxis use.
    PLoS One. 2023;18:e0296054.
    >> Share

    January 2022
  45. SUZUKI K, Suda G, Yamamoto Y, Abiko S, et al
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 2022;17:e0261760.
    >> Share

  46. TADESSE WT, Adankie BT, Shibeshi W, Amogne W, et al
    Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
    PLoS One. 2022;17:e0262604.
    >> Share

  47. CUCO RM, Loquiha O, Juga A, Couto A, et al
    Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PLoS One. 2022;17:e0261522.
    >> Share

  48. UCHIDA Y, Nakao M, Yamada S, Tsuji S, et al
    Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    PLoS One. 2022;17:e0262764.
    >> Share

  49. KANGUYA T, Koyuncu A, Sharma A, Kusanathan T, et al
    Identifying barriers to ART initiation and adherence: An exploratory qualitative study on PMTCT in Zambia.
    PLoS One. 2022;17:e0262392.
    >> Share

  50. LULSEGED S, Melaku Z, Habteselassie A, West CA, et al
    Progress towards controlling the HIV epidemic in urban Ethiopia: Findings from the 2017-2018 Ethiopia population-based HIV impact assessment survey.
    PLoS One. 2022;17:e0264441.
    >> Share

  51. STONER MCD, Browne EN, Gundacker HM, Hawley I, et al
    Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    PLoS One. 2022;17:e0263664.
    >> Share

  52. NGAYO MO, Oluka M, Kwena ZA, Bulimo WD, et al
    Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    PLoS One. 2022;17:e0260872.
    >> Share

  53. T TCHAKOUTE C, Rhee SY, Hare CB, Shafer RW, et al
    Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system.
    PLoS One. 2022;17:e0263742.
    >> Share

  54. MARTINEZ CA, Rikhi R, Pester MS, Parker M, et al
    Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.
    PLoS One. 2022;17:e0264445.
    >> Share

  55. FENTIE WENDIE T, Mengistu G
    Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.
    PLoS One. 2022;17:e0265337.
    >> Share

  56. FISEHA T, Ebrahim H, Ebrahim E, Gebreweld A, et al
    CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
    PLoS One. 2022;17:e0265740.
    >> Share

  57. KIM JH, Jiamsakul A, Kiertiburanakul S, Huy BV, et al
    Patterns and prognosis of holding regimens for people living with HIV in Asian countries.
    PLoS One. 2022;17:e0264157.
    >> Share

  58. HONG SY, Winston A, Mutenda N, Hamunime N, et al
    Predictors of loss to follow-up from HIV antiretroviral therapy in Namibia.
    PLoS One. 2022;17:e0266438.
    >> Share

  59. VELLOZA J, Poovan N, Ndlovu N, Khoza N, et al
    Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
    PLoS One. 2022;17:e0266665.
    >> Share

  60. EJIGU S, Haile D, Solomon Y
    Effect of malaria and HIV/AIDS co-infection on red blood cell indices and its relation with the CD4 level of patients on HAART in Bench Sheko Zone, Southwest Ethiopia.
    PLoS One. 2022;17:e0263865.
    >> Share

  61. ELMEKATY EZI, Alibrahim R, Hassanin R, Eltaib S, et al
    Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
    PLoS One. 2022;17:e0267884.
    >> Share

  62. HONG W, Park YK, Kim BO, Park SK, et al
    Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.
    PLoS One. 2022;17:e0267645.
    >> Share

  63. ROSENTHAL EM, Rosenberg ES, Patterson W, Ferguson WP, et al
    Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State.
    PLoS One. 2022;17:e0268978.
    >> Share

  64. ACHILA OO, Abrhaley F, Kesete Y, Tesfaldet F, et al
    Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea.
    PLoS One. 2022;17:e0270838.
    >> Share

  65. SKRZAT-KLAPACZYNSKA A, Paciorek M, Horban A, Kowalska JD, et al
    Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients.
    PLoS One. 2022;17:e0270770.
    >> Share

  66. AKTER Y, Barua R, Nasir Uddin M, Muhammad Sanaullah AF, et al
    Bioactive potentiality of secondary metabolites from endophytic bacteria against SARS-COV-2: An in-silico approach.
    PLoS One. 2022;17:e0269962.
    >> Share

  67. MESIC A, Decroo T, Mar HT, Jacobs BKM, et al
    Viraemic-time predicts mortality among people living with HIV on second-line antiretroviral treatment in Myanmar: A retrospective cohort study.
    PLoS One. 2022;17:e0271910.
    >> Share

  68. BUSKIN SE, Lechtenberg RJ, Slaughter FA, Herbeck JT, et al
    A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis.
    PLoS One. 2022;17:e0272958.
    >> Share

  69. EBONWU J, Lassauniere R, Paximadis M, Strehlau R, et al
    FCGR3A gene duplication, FcgammaRIIb-232TT and FcgammaRIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1.
    PLoS One. 2022;17:e0273933.
    >> Share

  70. MWAMUYE IC, Karanja S, Msanzu JB, Adem A, et al
    Factors associated with poor outcomes among people living with HIV started on anti-retroviral therapy before and after implementation of "test and treat" program in Coastal Kenya.
    PLoS One. 2022;17:e0270653.
    >> Share

  71. KARONEY MJ, Koech MK, Njiru EW, Owino Ong'or WD, et al
    Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
    PLoS One. 2022;17:e0273183.
    >> Share

  72. BOYCE CL, Beck IA, Styrchak SM, Hardy SR, et al
    Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    PLoS One. 2022;17:e0275254.
    >> Share

  73. THURMAN AR, Brache V, Cochon L, Ouattara LA, et al
    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    PLoS One. 2022;17:e0275794.
    >> Share

  74. GOODE-ROMERO G, Dominguez L
    Computational study of the structural ensemble of CC chemokine receptor type 5 (CCR5) and its interactions with different ligands.
    PLoS One. 2022;17:e0275269.
    >> Share

  75. PENDA CI, Moukoko Mbonjo M, Fokam J, Djeuda ABD, et al
    Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
    PLoS One. 2022;17:e0276730.
    >> Share

  76. NAKIGANDA LJ, Grulich AE, Poynten IM, Serwadda D, et al
    Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda.
    PLoS One. 2022;17:e0277226.
    >> Share

  77. KIMANGA DO, Oramisi VA, Hassan AS, Mugambi MK, et al
    Uptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in Kenya.
    PLoS One. 2022;17:e0277675.
    >> Share

  78. WATTANACHANYA L, Sunthornyothin S, Apornpong T, Lwin HMS, et al
    Bone mineral density among virologically suppressed Asians older than 50 years old living with and without HIV: A cross-sectional study.
    PLoS One. 2022;17:e0277231.
    >> Share

  79. CABELLO-UBEDA A, de Quiros JCLB, Martin Carbonero L, Sanz J, et al
    48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naive adults living with HIV: A multicenter real-life cohort.
    PLoS One. 2022;17:e0277606.
    >> Share

  80. HSIAO K, Zegzouti H, Goueli S
    High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases.
    PLoS One. 2022;17:e0274343.
    >> Share

  81. ZHU J, Huang H, Wang M, Zhang Y, et al
    High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients receiving long-term antiviral therapy.
    PLoS One. 2022;17:e0279731.
    >> Share

    January 2021
  82. MAPANGISANA T, Machekano R, Kouamou V, Maposhere C, et al
    Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.
    PLoS One. 2021;16:e0245085.
    >> Share

  83. KIMANI M, van der Elst EM, Chirro O, Wahome E, et al
    "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    PLoS One. 2021;16:e0244226.
    >> Share

  84. TYRBERG E, Eden A, Eriksen J, Nilsson S, et al
    Higher plasma drug levels in elderly people living with HIV treated with darunavir.
    PLoS One. 2021;16:e0246171.
    >> Share

  85. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    >> Share

  86. STRANIX-CHIBANDA L, Tierney C, Sebikari D, Aizire J, et al
    Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
    PLoS One. 2021;16:e0246272.
    >> Share

  87. GIOVENCO D, Gill K, Fynn L, Duyver M, et al
    Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence.
    PLoS One. 2021;16:e0248307.
    >> Share

  88. JUUL S, Nielsen EE, Feinberg J, Siddiqui F, et al
    Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
    PLoS One. 2021;16:e0248132.
    >> Share

  89. BITARAKWATE E, Ashburn K, Kazooba P, Khamasi R, et al
    Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
    PLoS One. 2021;16:e0247507.
    >> Share

  90. TAGNOUOKAM-NGOUPO PA, Penda IC, Tchatchueng Mbougua JB, Tetang Ndiang S, et al
    Virological failure and antiretroviral resistance among HIV-infected children after five years follow-up in the ANRS 12225-PEDIACAM cohort in Cameroon.
    PLoS One. 2021;16:e0248642.
    >> Share

  91. RUBIO-GARRIDO M, Reina G, Ndarabu A, Rodriguez-Galet A, et al
    High drug resistance levels could compromise the control of HIV infection in paediatric and adolescent population in Kinshasa, the Democratic Republic of Congo.
    PLoS One. 2021;16:e0248835.
    >> Share

  92. KINAI E, Nguyen HDT, Do HQ, Matsumoto S, et al
    Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health.
    PLoS One. 2021;16:e0250828.
    >> Share

  93. SALTO-ALEJANDRE S, Jimenez-Jorge S, Sabe N, Ramos-Martinez A, et al
    Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study.
    PLoS One. 2021;16:e0250796.
    >> Share

  94. FRENKEL LM, Kuller L, Beck IA, Tsai CC, et al
    Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge.
    PLoS One. 2021;16:e0240495.
    >> Share

  95. COTA JM, Benavides TM, Fields JD, Jansen N, et al
    High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
    PLoS One. 2021;16:e0250607.
    >> Share

  96. PAN CQ, Chang TT, Bae SH, Brunetto M, et al
    Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    PLoS One. 2021;16:e0251552.
    >> Share


  97. Correction: Higher plasma drug levels in elderly people living with HIV treated with darunavir.
    PLoS One. 2021;16:e0251856.
    >> Share

  98. SCHNEIDER J, Jaenigen B, Wagner D, Rieg S, et al
    Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
    PLoS One. 2021;16:e0249760.
    >> Share

  99. SILVA M, Montes CG, Canals A, Mackenna MJ, et al
    Role and effects of zinc supplementation in HIV-infected patients with immunovirological discordance: A randomized, double blind, case control study.
    PLoS One. 2021;16:e0244823.
    >> Share

  100. AKATUKWASA C, Getahun M, El Ayadi AM, Namanya J, et al
    Dimensions of HIV-related stigma in rural communities in Kenya and Uganda at the start of a large HIV 'test and treat' trial.
    PLoS One. 2021;16:e0249462.
    >> Share

  101. A MALHANI A, A Enani M, Saheb Sharif-Askari F, R Alghareeb M, et al
    Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
    PLoS One. 2021;16:e0252984.
    >> Share

  102. PILOYA TW, Bakeera-Kitaka S, Kisitu GP, Idro R, et al
    Vitamin D status and associated factors among HIV-infected children and adolescents on antiretroviral therapy in Kampala, Uganda.
    PLoS One. 2021;16:e0253689.
    >> Share

  103. PURWATI, Miatmoko A, Nasronudin, Hendrianto E, et al
    An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
    PLoS One. 2021;16:e0252302.
    >> Share

  104. NKA AD, Teto G, Santoro MM, Ngum Ndze V, et al
    HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol.
    PLoS One. 2021;16:e0253587.
    >> Share

  105. CHABALA FW, Siew ED, Mutale W, Mulenga L, et al
    Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
    PLoS One. 2021;16:e0252768.
    >> Share

  106. DE FRANCESCO D, Wang X, Dickinson L, Underwood J, et al
    Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.
    PLoS One. 2021;16:e0253861.
    >> Share

  107. HAMOOYA BM, Musonda P, Mutale W, Masenga SK, et al
    Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings.
    PLoS One. 2021;16:e0247004.
    >> Share

  108. HOULE B, Kabudula CW, Stein A, Gareta D, et al
    Linking the timing of a mother's and child's death: Comparative evidence from two rural South African population-based surveillance studies, 2000-2015.
    PLoS One. 2021;16:e0246671.
    >> Share

  109. STRANIX-CHIBANDA L, Tierney C, Pinilla M, George K, et al
    Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
    PLoS One. 2021;16:e0255250.
    >> Share

  110. CONAN N, Paye CP, Ortuno R, Chijuwa A, et al
    What gaps remain in the HIV cascade of care? Results of a population-based survey in Nsanje District, Malawi.
    PLoS One. 2021;16:e0248410.
    >> Share

  111. SOHRABY F, Aryapour H
    Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by supervised molecular dynamics simulation.
    PLoS One. 2021;16:e0257916.
    >> Share

  112. FISEHA T, Alemu W, Dereje H, Tamir Z, et al
    Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia.
    PLoS One. 2021;16:e0250328.
    >> Share

  113. BACHANAS P, Alwano MG, Lebelonyane R, Block L, et al
    Finding, treating and retaining persons with HIV in a high HIV prevalence and high treatment coverage country: Results from the Botswana Combination Prevention Project.
    PLoS One. 2021;16:e0250211.
    >> Share

  114. KANG SH, Cho DH, Choi J, Baik SK, et al
    Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
    PLoS One. 2021;16:e0258229.
    >> Share

  115. MOHAMMED SA, Yitafr MG, Workneh BD, Hailu AD, et al
    Health-related quality of life and associated factors among people living with human immunodeficiency virus on highly active antiretroviral therapy in North East Ethiopia: Cross-sectional study.
    PLoS One. 2021;16:e0247777.
    >> Share

  116. GISSLEN M, Keating SM, Spudich S, Arechiga V, et al
    Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.
    PLoS One. 2021;16:e0250987.
    >> Share

  117. EASTMENT MC, Kinuthia J, Wang L, Wanje G, et al
    Late antiretroviral refills and condomless sex in a cohort of HIV-seropositive pregnant and postpartum Kenyan women.
    PLoS One. 2021;16:e0254767.
    >> Share

  118. JIANU C, Itu-Muresan C, Drugan C, Filipescu I, et al
    Evaluation of several serum interleukins as markers for treatment effectiveness in naive HIV infected patients: A pilot study.
    PLoS One. 2021;16:e0260007.
    >> Share

  119. HANLEY S, Moodley D, Naidoo M
    Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease.
    PLoS One. 2021;16:e0255652.
    >> Share

  120. BISNAUTH MA, Davies N, Monareng S, Buthelezi F, et al
    Why do patients interrupt and return to antiretroviral therapy? Retention in HIV care from the patient's perspective in Johannesburg, South Africa.
    PLoS One. 2021;16:e0256540.
    >> Share

  121. ROHWER A, Hendricks L, Oliver S, Garner P, et al
    Testing for saturation in qualitative evidence syntheses: An update of HIV adherence in Africa.
    PLoS One. 2021;16:e0258352.
    >> Share

  122. NGUYEN QT, Ishizaki A, Bi X, Matsuda K, et al
    Alterations in children's sub-dominant gut microbiota by HIV infection and anti-retroviral therapy.
    PLoS One. 2021;16:e0258226.
    >> Share

  123. BISETEGN H, Ebrahim H
    The prevalence of thrombocytopenia and leucopenia among people living with HIV/AIDS in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0257630.
    >> Share

  124. BAYLEYEGN B, Kifle ZD, Geremew D
    Virological failure and associated factors among children receiving anti-retroviral therapy, Northwest Ethiopia.
    PLoS One. 2021;16:e0257204.
    >> Share

  125. LEBELONYANE R, Bachanas P, Block L, Ussery F, et al
    To achieve 95-95-95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach.
    PLoS One. 2021;16:e0255227.
    >> Share

  126. FOCA E, Calcagno A, Calza S, Renzetti S, et al
    Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
    PLoS One. 2021;16:e0258533.
    >> Share

  127. LEE SW, Kim SM, Hur W, Kang BY, et al
    Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.
    PLoS One. 2021;16:e0261067.
    >> Share

  128. MAPESI H, Okuma J, Franzeck F, Wilson HI, et al
    Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania.
    PLoS One. 2021;16:e0261367.
    >> Share

  129. DAVID D, Kedem E, Turner D, Levy I, et al
    Long term dual antiretroviral therapy: A real life retrospective countrywide Israeli study.
    PLoS One. 2021;16:e0259271.
    >> Share

  130. CHOHAN BH, Ronen K, Khasimwa B, Matemo D, et al
    Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment.
    PLoS One. 2021;16:e0256249.
    >> Share

  131. CHINGOMBE I, Mapingure MP, Balachandra S, Chipango TN, et al
    Patient costs for prevention of mother-to-child HIV transmission and antiretroviral therapy services in public health facilities in Zimbabwe.
    PLoS One. 2021;16:e0256291.
    >> Share

  132. NGONGO NM, Darcis G, Nanituna HS, Mambimbi MM, et al
    Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017.
    PLoS One. 2021;16:e0259073.
    >> Share

  133. YESHANEH A, Lencha A, Aweke AM, Dessalew Y, et al
    Consistent condom utilization and associated factors among HIV positive clients attending ART clinic at Pawi general hospital, North West Ethiopia.
    PLoS One. 2021;16:e0261581.
    >> Share

  134. GRANT-MCAULEY W, Klock E, Laeyendecker O, Piwowar-Manning E, et al
    Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART).
    PLoS One. 2021;16:e0258644.
    >> Share

  135. CASTRO-GRANELL V, Garin N, Jaen A, Cenoz S, et al
    Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain.
    PLoS One. 2021;16:e0260334.
    >> Share

    January 2020
  136. BLANCO JR, Alejos B, Moreno S
    Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).
    PLoS One. 2020;15:e0226724.
    >> Share

  137. CHISATI EM, Constantinou D, Lampiao F
    Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors.
    PLoS One. 2020;15:e0227893.
    >> Share

  138. VINIKOOR MJ, Sinkala E, Kanunga A, Muchimba M, et al
    Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia.
    PLoS One. 2020;15:e0227041.
    >> Share

  139. AUCLAIR M, Guenantin AC, Fellahi S, Garcia M, et al
    HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
    PLoS One. 2020;15:e0226924.
    >> Share

  140. ATUHAIRE P, S Brummel S, Mmbaga BT, Angelidou K, et al
    The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial.
    PLoS One. 2020;15:e0228003.
    >> Share

  141. HUHN GD, Ramgopal M, Jain MK, Hinestrosa F, et al
    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PLoS One. 2020;15:e0224875.
    >> Share

  142. LIN SF, Tung SY, Wei KL, Chen CH, et al
    Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    PLoS One. 2020;15:e0229994.
    >> Share

  143. HAN WM, Wattanachanya L, Apornpong T, Jantrapakde J, et al
    Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    PLoS One. 2020;15:e0230368.
    >> Share

  144. UDEZE AO, Olaleye DO, Odaibo GN
    Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.
    PLoS One. 2020;15:e0231031.
    >> Share

  145. TESHALE AB, Tsegaye AT, Wolde HF
    Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling.
    PLoS One. 2020;15:e0227473.
    >> Share

  146. LAHUERTA M, Syowai M, Vakil S, Odhiambo J, et al
    Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
    PLoS One. 2020;15:e0232104.
    >> Share

  147. HAREZLAK J, Sarwat S, Wools-Kaloustian K, Schomaker M, et al
    PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration.
    PLoS One. 2020;15:e0220165.
    >> Share

  148. GANGCUANGCO LMA, Mitchell BI, Siriwardhana C, Kohorn LB, et al
    Mitochondrial oxidative phosphorylation in peripheral blood mononuclear cells is decreased in chronic HIV and correlates with immune dysregulation.
    PLoS One. 2020;15:e0231761.
    >> Share

  149. CHITONGO R, Obasa AE, Mikasi SG, Jacobs GB, et al
    Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    PLoS One. 2020;15:e0223464.
    >> Share

  150. SCHUTTE C, Forsythe S, Mdala JF, Zieman B, et al
    The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia.
    PLoS One. 2020;15:e0228135.
    >> Share

  151. NYAKATO P, Davies MA, Technau KG, Fatti G, et al
    Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
    PLoS One. 2020;15:e0233693.
    >> Share

  152. WOLDESENBET S, Kufa T, Cheyip M, Ayalew K, et al
    Awareness of HIV-positive status and linkage to treatment prior to pregnancy in the "test and treat" era: A national antenatal sentinel survey, 2017, South Africa.
    PLoS One. 2020;15:e0229874.
    >> Share

  153. BASSON AE, Charalambous S, Hoffmann CJ, Morris L, et al
    HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
    PLoS One. 2020;15:e0234937.
    >> Share

  154. AREFAINE ZG, Abebe S, Bekele E, Adem A, et al
    Incidence and predictors of HIV related opportunistic infections after initiation of highly active antiretroviral therapy at Ayder Referral Hospital, Mekelle, Ethiopia: A retrospective single centered cohort study.
    PLoS One. 2020;15:e0229757.
    >> Share

  155. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    >> Share

  156. MASHINGAIDZE-MANO R, Bwakura-Dangarembizi MF, Maponga CC, Morse GD, et al
    Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
    PLoS One. 2020;15:e0235759.
    >> Share

  157. CHALOUNI M, Rodriguez-Centeno J, Samri A, Blanco J, et al
    Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.
    PLoS One. 2020;15:e0230772.
    >> Share

  158. KIWANUKA J, Mukulu Waila J, Muhindo Kahungu M, Kitonsa J, et al
    Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.
    PLoS One. 2020;15:e0217606.
    >> Share

  159. TEASDALE CA, Abrams EJ, Yuengling KA, Lamb MR, et al
    Expansion and scale-up of HIV care and treatment services in four countries over ten years.
    PLoS One. 2020;15:e0231667.
    >> Share

  160. ZHOU H, Zhu M, Ma L, Zhou J, et al
    Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
    PLoS One. 2020;15:e0235483.
    >> Share

  161. BERENGUER J, Parrondo J, Landovitz RJ
    Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model.
    PLoS One. 2020;15:e0236032.
    >> Share

  162. NABITAKA VM, Nawaggi P, Campbell J, Conroy J, et al
    High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
    PLoS One. 2020;15:e0232419.
    >> Share

  163. WOLDAY D, Kebede Y, Legesse D, Siraj DS, et al
    Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade.
    PLoS One. 2020;15:e0233049.
    >> Share

  164. ARERI HA, Marshall A, Harvey G
    Interventions to improve self-management of adults living with HIV on Antiretroviral Therapy: A systematic review.
    PLoS One. 2020;15:e0232709.
    >> Share

  165. ABADIGA M, Hasen T, Mosisa G, Abdisa E, et al
    Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019.
    PLoS One. 2020;15:e0232703.
    >> Share

  166. TCHOUNGA BK, Charpentier C, Coffie PA, Dabis F, et al
    Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
    PLoS One. 2020;15:e0236642.
    >> Share

  167. YU HC, Lin KH, Tsay FW, Tsai TJ, et al
    Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies.
    PLoS One. 2020;15:e0237586.
    >> Share

  168. MIKULSKA M, Nicolini LA, Signori A, Di Biagio A, et al
    Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    PLoS One. 2020;15:e0237831.
    >> Share

  169. MITI S, Handema R, Mulenga L, Mwansa JK, et al
    Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    PLoS One. 2020;15:e0236156.
    >> Share

  170. ROWELL-CUNSOLO TL, Hu G
    Barriers to optimal antiretroviral therapy adherence among HIV-infected formerly incarcerated individuals in New York City.
    PLoS One. 2020;15:e0233842.
    >> Share

  171. LAIN MG, Chicumbe S, de Araujo AR, Karajeanes E, et al
    Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique.
    PLoS One. 2020;15:e0237993.
    >> Share

  172. SINGH S, Toor JS, Sharma A, Arora SK, et al
    Signature genes associated with immunological non-responsiveness to anti-retroviral therapy in HIV-1 subtype-c infection.
    PLoS One. 2020;15:e0234270.
    >> Share

  173. FEARON E, Tenza S, Mokoena C, Moodley K, et al
    HIV testing, care and viral suppression among men who have sex with men and transgender individuals in Johannesburg, South Africa.
    PLoS One. 2020;15:e0234384.
    >> Share

  174. KATO I, Tumaini B, Pallangyo K
    Prevalence of non-communicable diseases among individuals with HIV infection by antiretroviral therapy status in Dar es Salaam, Tanzania.
    PLoS One. 2020;15:e0235542.
    >> Share

  175. MUYINDIKE WR, Fatch R, Cheng DM, Emenyonu NI, et al
    Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda.
    PLoS One. 2020;15:e0235261.
    >> Share

  176. NEGREDO E, Jimenez M, Puig J, Loste C, et al
    A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
    PLoS One. 2020;15:e0238575.
    >> Share

  177. TAMANDJOU TCHUEM CR, Brandt L, Nel ER, Cotton MF, et al
    Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
    PLoS One. 2020;15:e0238839.
    >> Share

  178. KAHLERT CR, Cipriani M, Vernazza P
    Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.
    PLoS One. 2020;15:e0237770.
    >> Share

  179. CAVALCANTI ATAE, de Alencar Ximenes RA, Montarroyos UR, d'Albuquerque PM, et al
    Effectiveness of four antiretroviral regimens for treating people living with HIV.
    PLoS One. 2020;15:e0239527.
    >> Share

  180. GIRAUD JS, Doisne M, Chan Hew Wai A, Majerholc C, et al
    De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.
    PLoS One. 2020;15:e0239704.
    >> Share

  181. BERNARD C, Font H, Diallo Z, Ahonon R, et al
    Prevalence and factors associated with physical function limitation in older West African people living with HIV.
    PLoS One. 2020;15:e0240906.
    >> Share

  182. SARTESCHI G, Di Biagio A, Foca E, Taramasso L, et al
    Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection.
    PLoS One. 2020;15:e0240550.
    >> Share

  183. NAPYO A, Tylleskar T, Mukunya D, Tumuhamye J, et al
    Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
    PLoS One. 2020;15:e0240529.
    >> Share

  184. SINDELAR K, Maponga C, Lekoala F, Mandara E, et al
    Beyond the facility: An evaluation of seven community-based pediatric HIV testing strategies and linkage to care outcomes in a high prevalence, resource-limited setting.
    PLoS One. 2020;15:e0236985.
    >> Share

  185. DI YACOVO S, Saumoy M, Sanchez-Quesada JL, Navarro A, et al
    Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.
    PLoS One. 2020;15:e0237739.
    >> Share

  186. RICH SN, Cook RL, Yaghjyan L, Francois K, et al
    Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017.
    PLoS One. 2020;15:e0240817.
    >> Share

  187. PLATT L, Xu A, Giddy J, Bogart LM, et al
    Identifying and predicting longitudinal trajectories of care for people newly diagnosed with HIV in South Africa.
    PLoS One. 2020;15:e0238975.
    >> Share

  188. DESTA A, Biru TT, Kefale AT
    Health related quality of life of people receiving highly active antiretroviral therapy in Southwest Ethiopia.
    PLoS One. 2020;15:e0237013.
    >> Share

  189. GEBREWELD A, Fiseha T, Girma N, Haileslasie H, et al
    Prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia.
    PLoS One. 2020;15:e0239215.
    >> Share

  190. MULISA D, Tolossa T, Wakuma B, Etafa W, et al
    Magnitude of first line antiretroviral therapy treatment failure and associated factors among adult patients on ART in South West Shoa, Central Ethiopia.
    PLoS One. 2020;15:e0241768.
    >> Share

  191. IWUJI C, Chimukuche RS, Zuma T, Plazy M, et al
    Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.
    PLoS One. 2020;15:e0239513.
    >> Share

  192. BONIATTI MM, Pellegrini JAS, Marques LS, John JF, et al
    Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial.
    PLoS One. 2020;15:e0239452.
    >> Share

  193. SARKAR A, Balogun K, Guzman Lenis MS, Acosta S, et al
    In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
    PLoS One. 2020;15:e0242513.
    >> Share

  194. KALLIANPUR AR, Wen W, Erwin AL, Clifford DB, et al
    Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy.
    PLoS One. 2020;15:e0239758.
    >> Share

  195. GRANT-MCAULEY W, Fogel JM, Galai N, Clarke W, et al
    Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic.
    PLoS One. 2020;15:e0240890.
    >> Share

  196. WOLDAY D, Legesse D, Kebede Y, Siraj DS, et al
    Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia.
    PLoS One. 2020;15:e0240880.
    >> Share

  197. MAKURUMIDZE R, Buyze J, Decroo T, Lynen L, et al
    Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in Zimbabwe.
    PLoS One. 2020;15:e0240865.
    >> Share

  198. MUWONGE TR, Nsubuga R, Brown C, Nakyanzi A, et al
    Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda.
    PLoS One. 2020;15:e0241399.
    >> Share

  199. BAM NE, Mabunda SA, Ntsaba J, Apalata T, et al
    The association between HIV tri-therapy with the development of Type-2 Diabetes Mellitus in a rural South African District: A case-control study.
    PLoS One. 2020;15:e0244067.
    >> Share

  200. MELLGREN A, Eriksson LE, Reinius M, Marrone G, et al
    Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    PLoS One. 2020;15:e0242710.
    >> Share

  201. SIKOMBE K, Mody A, Kadota J, Pry JJ, et al
    Understanding patient transfers across multiple clinics in Zambia among HIV infected adults.
    PLoS One. 2020;15:e0241477.
    >> Share

  202. ADRAWA N, Alege JB, Izudi J
    Alcohol consumption increases non-adherence to ART among people living with HIV enrolled to the community-based care model in rural northern Uganda.
    PLoS One. 2020;15:e0242801.
    >> Share

  203. YIN DE, Ludema C, Cole SR, Golin CE, et al
    Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
    PLoS One. 2020;15:e0242405.
    >> Share

  204. CICCACCI F, Lucaroni F, Latagliata R, Morciano L, et al
    Hematologic alterations and early mortality in a cohort of HIV positive African patients.
    PLoS One. 2020;15:e0242068.
    >> Share

  205. SAZONOVA Y, Kulchynska R, Sereda Y, Azarskova M, et al
    HIV treatment cascade among people who inject drugs in Ukraine.
    PLoS One. 2020;15:e0244572.
    >> Share

    January 2019
  206. SOLDI GFR, Ribeiro IC, Ahagon CM, Coelho LPO, et al
    Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in Sao Paulo State, Brazil.
    PLoS One. 2019;14:e0223210.
    >> Share

  207. MUSSINI C, Roncaglia E, Borghi V, Rusconi S, et al
    A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naive patients with CD4<200 cells/uL (the PRADAR study).
    PLoS One. 2019;14:e0222650.
    >> Share

  208. MA TL, Hu TH, Hung CH, Wang JH, et al
    Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
    PLoS One. 2019;14:e0222221.
    >> Share

  209. TARAMASSO L, Di Biagio A, Riccardi N, Briano F, et al
    Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    PLoS One. 2019;14:e0223181.
    >> Share

  210. MUKUMBANG FC, van Wyk B, Van Belle S, Marchal B, et al
    Unravelling how and why the Antiretroviral Adherence Club Intervention works (or not) in a public health facility: A realist explanatory theory-building case study.
    PLoS One. 2019;14:e0210565.
    >> Share

  211. GHANNAD M, Dennehy M, la Porte C, Seguin I, et al
    A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.
    PLoS One. 2019;14:e0223969.
    >> Share

  212. SHAMU S, Slabbert J, Guloba G, Blom D, et al
    Linkage to care of HIV positive clients in a community based HIV counselling and testing programme: A success story of non-governmental organisations in a South African district.
    PLoS One. 2019;14:e0210826.
    >> Share

  213. PERDOMO-CELIS F, Velilla PA, Taborda NA, Rugeles MT, et al
    An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression.
    PLoS One. 2019;14:e0210540.
    >> Share

  214. BLACKARD JT, Kong L, Rouster SD, Karns R, et al
    CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PLoS One. 2019;14:e0224523.
    >> Share

  215. MEYER-RATH G, van Rensburg C, Chiu C, Leuner R, et al
    The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case.
    PLoS One. 2019;14:e0210497.
    >> Share

  216. HASSAN AS, Bibby DF, Mwaringa SM, Agutu CA, et al
    Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya.
    PLoS One. 2019;14:e0210559.
    >> Share

  217. PILLAI N, Foster N, Hanifa Y, Ndlovu N, et al
    Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa.
    PLoS One. 2019;14:e0210622.
    >> Share

  218. DALY MB, Clayton AM, Ruone S, Mitchell J, et al
    Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies.
    PLoS One. 2019;14:e0225146.
    >> Share

  219. ROSS LL, Walker AS, Lou Y, Tenorio AR, et al
    Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs >/=50 m
    PLoS One. 2019;14:e0225199.
    >> Share

  220. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    >> Share

  221. SAVASI V, Parisi F, Oneta M, Laoreti A, et al
    Effects of highly active antiretroviral therapy on semen parameters of a cohort of 770 HIV-1 infected men.
    PLoS One. 2019;14:e0212194.
    >> Share

  222. YIRDAW KD, Teklu AM, Mamuye AT, Zewdu S, et al
    Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study.
    PLoS One. 2019;14:e0211688.
    >> Share

  223. DE LUCA A, Pezzotti P, Boucher C, Doring M, et al
    Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey.
    PLoS One. 2019;14:e0225381.
    >> Share

  224. CHEN MB, Wang H, Zheng QH, Zheng XW, et al
    Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0224773.
    >> Share

  225. LEONE A, de Gennaro N, Fabrizio C, Scudeller L, et al
    HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio.
    PLoS One. 2019;14:e0212882.
    >> Share

  226. MENON S, Rossi R, Kariisa M, Acharya SD, et al
    Relationship between Highly Active Antiretroviral Therapy (HAART) and human papillomavirus type 16 (HPV 16) infection among women in Sub-Saharan Africa and public health implications: A systematic review.
    PLoS One. 2019;14:e0213086.
    >> Share

  227. HERMANSSON L, Yilmaz A, Price RW, Nilsson S, et al
    Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    PLoS One. 2019;14:e0226276.
    >> Share

  228. AYANA DA, Mulu A, Mihret A, Seyoum B, et al
    Hepatitis B virus seromarkers among HIV infected adults on ART: An unmet need for HBV screening in eastern Ethiopia.
    PLoS One. 2019;14:e0226922.
    >> Share

  229. RESTREPO C, Gutierrez-Rivas M, Pacheco YM, Garcia M, et al
    Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression.
    PLoS One. 2019;14:e0214421.
    >> Share

  230. LIMMADE Y, Fransisca L, Rodriguez-Fernandez R, Bangs MJ, et al
    HIV treatment outcomes following antiretroviral therapy initiation and monitoring: A workplace program in Papua, Indonesia.
    PLoS One. 2019;14:e0212432.
    >> Share

  231. YUMO HA, Ajeh RA, Beissner M, Ndenkeh JN Jr, et al
    Effectiveness of symptom-based diagnostic HIV testing versus targeted and blanket provider-initiated testing and counseling among children and adolescents in Cameroon.
    PLoS One. 2019;14:e0214251.
    >> Share

  232. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    >> Share

  233. ANGDEMBE MR, Rai A, Bam K, Pandey SR, et al
    Predictors of mortality in adult people living with HIV on antiretroviral therapy in Nepal: A retrospective cohort study, 2004-2013.
    PLoS One. 2019;14:e0215776.
    >> Share

  234. KUFA T, Shubber Z, MacLeod W, Takuva S, et al
    CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
    PLoS One. 2019;14:e0217742.
    >> Share

  235. KREBS E, Enns B, Wang L, Zang X, et al
    Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis.
    PLoS One. 2019;14:e0217559.
    >> Share

  236. VENABLES E, Towriss C, Rini Z, Nxiba X, et al
    Patient experiences of ART adherence clubs in Khayelitsha and Gugulethu, Cape Town, South Africa: A qualitative study.
    PLoS One. 2019;14:e0218340.
    >> Share

  237. STAFFORD KA, Odafe SF, Lo J, Ibrahim R, et al
    Evaluation of the clinical outcomes of the Test and Treat strategy to implement Treat All in Nigeria: Results from the Nigeria Multi-Center ART Study.
    PLoS One. 2019;14:e0218555.
    >> Share

  238. LASRY A, Kalou MB, Young PR, Rurangirwa J, et al
    Cost implications of HIV retesting for verification in Africa.
    PLoS One. 2019;14:e0218936.
    >> Share

  239. DOLD L, Nielsen MJ, Praktiknjo M, Schwarze-Zander C, et al
    Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
    PLoS One. 2019;14:e0219526.
    >> Share

  240. KANSIIME S, Mwesigire D, Mugerwa H
    Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda.
    PLoS One. 2019;14:e0221022.
    >> Share

  241. SOFEU CL, Tejiokem MC, Penda CI, Protopopescu C, et al
    Early treated HIV-infected children remain at risk of growth retardation during the first five years of life: Results from the ANRS-PEDIACAM cohort in Cameroon.
    PLoS One. 2019;14:e0219960.
    >> Share

  242. REIDY W, Nuwagaba-Biribonwoha H, Shongwe S, Sahabo R, et al
    Engagement in care among women and their infants lost to follow-up under Option B+ in eSwatini.
    PLoS One. 2019;14:e0222959.
    >> Share

  243. NYATHI S, Dlodlo RA, Satyanarayana S, Takarinda KC, et al
    Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
    PLoS One. 2019;14:e0223076.
    >> Share

  244. GENBERG BL, Hogan JW, Xu Y, Nyambura M, et al
    Population-based estimates of engagement in HIV care and mortality using double-sampling methods following home-based counseling and testing in western Kenya.
    PLoS One. 2019;14:e0223187.
    >> Share

  245. PRICE JT, Vwalika B, Hobbs M, Nelson JAE, et al
    Highly diverse anaerobe-predominant vaginal microbiota among HIV-infected pregnant women in Zambia.
    PLoS One. 2019;14:e0223128.
    >> Share

  246. PINEDA-PENA AC, Pingarilho M, Li G, Vrancken B, et al
    Drivers of HIV-1 transmission: The Portuguese case.
    PLoS One. 2019;14:e0218226.
    >> Share

  247. MARUKUTIRA T, Block L, Alwano MG, Behel S, et al
    Comparison of knowledge of HIV status and treatment coverage between non-citizens and citizens: Botswana Combination Prevention Project (BCPP).
    PLoS One. 2019;14:e0221629.
    >> Share

  248. GUILLEN S, Prieto L, Jimenez de Ory S, Gonzalez-Tome MI, et al
    Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children.
    PLoS One. 2019;14:e0220552.
    >> Share

  249. ADAMS JW, Lurie MN, King MRF, Brady KA, et al
    Decreasing HIV transmissions to African American women through interventions for men living with HIV post-incarceration: An agent-based modeling study.
    PLoS One. 2019;14:e0219361.
    >> Share

  250. MUGGLIN C, Haas AD, van Oosterhout JJ, Msukwa M, et al
    Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study.
    PLoS One. 2019;14:e0224837.
    >> Share

  251. SAMPERIZ G, Fanjul F, Valera JL, Lopez M, et al
    Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART.
    PLoS One. 2019;14:e0224510.
    >> Share

  252. JERENE D, Abebe W, Taye K, Ruff A, et al
    Adolescents living with HIV are at higher risk of death and loss to follow up from care: Analysis of cohort data from eight health facilities in Ethiopia.
    PLoS One. 2019;14:e0223655.
    >> Share

  253. SILVERMAN RA, John-Stewart GC, Beck IA, Milne R, et al
    Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study.
    PLoS One. 2019;14:e0223411.
    >> Share

  254. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    >> Share

  255. MACHADO LY, Blanco M, Lopez LS, Diaz HM, et al
    National survey of pre-treatment HIV drug resistance in Cuban patients.
    PLoS One. 2019;14:e0221879.
    >> Share

  256. BORDONI V, Brando B, Piselli P, Forini O, et al
    Naive/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study.
    PLoS One. 2019;14:e0225415.
    >> Share

  257. DESTA AA, Wubayehu Woldearegay T, Berhe AA, Futwi N, et al
    Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on Antiretroviral Therapy in Northern Ethiopia: A retrospective cross sectional study.
    PLoS One. 2019;14:e0226293.
    >> Share

  258. QUAN V, Toro-Silva S, Sriruttan C, Chetty V, et al
    Pathways to care and outcomes among hospitalised HIV-seropositive persons with cryptococcal meningitis in South Africa.
    PLoS One. 2019;14:e0225742.
    >> Share

  259. VAN DEN HOF M, Ter Haar AM, Scherpbier HJ, Reiss P, et al
    Lower IQ and poorer cognitive profiles in treated perinatally HIV-infected children is irrespective of having a background of international adoption.
    PLoS One. 2019;14:e0224930.
    >> Share

  260. DUGDALE CM, Phillips TK, Myer L, Hyle EP, et al
    Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.
    PLoS One. 2019;14:e0225104.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016